World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
88599
World Ranking
2439
National Ranking
1382

Overview

Brian I. Rini is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily addresses the treatment and biology of renal cell carcinoma and related cancers, contributing to both clinical and molecular understanding within the oncology field.

Their publication record includes numerous works in leading medical and oncology journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • The Oncologist
  • ESMO Open

Their main fields of study encompass Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, their subfields cover Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Economics and Econometrics.

Brian I. Rini's research topics focus strongly on:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Pancreatic and Hepatic Oncology Research
  • Bladder and Urothelial Cancer Treatments

Recent papers reflect areas at the intersection of clinical oncology and immunotherapy. Notable publications include:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, 2020, The Lancet
  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade, 2020, Cancer Cell
  • The immunology of renal cell carcinoma, 2020, Nature Reviews Nephrology

Collaborations have been an integral part of their work, frequently co-authoring with researchers such as Toni K. Choueiri, Laurence Albigès, Robert J. Motzer, David F. McDermott, and Michael B. Atkins. These co-authors are prominent within oncology and related biomedical research, underlining a network focused on cancer treatment and translational studies.

Best Publications

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Renal cell carcinoma

    Brian I Rini;Steven C Campbell;Bernard Escudier

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Jennifer S. Ko;Arnold H. Zea;Brian I. Rini;Joanna L. Ireland

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Thomas Powles
Thomas Powles Queen Mary University of London
Michael B. Atkins
Michael B. Atkins Georgetown University
James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Steven C. Campbell
Steven C. Campbell Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering Medicine in the USA, there are multiple online degree options and career pathways to explore. Those already working as registered nurses might look into rn to bsn programs without clinicals. These programs are designed for flexibility, letting nurses advance their education without traditional in-person requirements.

For those interested in advancing further, doctoral nursing pathways offer accelerated options. The shortest dnp programs provide a streamlined route for qualified nurses to earn their Doctor of Nursing Practice in less time. Some students may also prefer easiest dnp programs, which focus on user-friendly curricula and manageable workloads.

If you’re just beginning your journey, consider starting with a fast lpn program. These online courses help students become Licensed Practical Nurses quickly, offering a stepping stone to further medical education and employment.

Exploring these varied online programs can help you find a pathway that suits your goals, schedule, and learning preferences as you pursue a career in medicine.

Best Scientists Citing Brian I. Rini

Trending Scientists

Recently Published Articles